Researchers at the University of New York Langon NYU Medical Center and Cancer Institute in New York has resulted in trials at the National Cancer Institute Early Detection Research Network Biomarker Discovery Lab with what they now call the biomarker most accurate in detecting proteins secreted by tumors asbestos cancer. The test results were SomaLogic aptamer Inc. proteomics platform presented at AACR 102: Annual Meeting 2011, e between April 2 and 6 site.
Scientists have found that the proteomic analysis detected 15 of 19 cases of malignant pleural mesothelioma who were in phase 1 or phase 2. Mesothelioma is a rare cancer that affects the protective lining of major organs and body cavities and is caused almost exclusively by exposure to asbestos. The pleural mesothelioma is specific to the lining of the lungs, which means that the platform specifically detects lung mesothelioma, but not necessarily the heart, chest or abdomen.
The test was considered 100% specific, meaning that there was one false positive in this study and its sensitivity was assessed at 80% to detect the presence of an early cancer. Mesothelioma is usually very difficult to detect and is usually diagnosed only when it becomes symptomatic around the scene three or four, which makes it difficult to treat and almost impossible to beat.
"Only patients who seem to benefit from treatment of mesothelioma are those who are in Stage 1 and this is only 10-15 percent of patients," said the head of the Division of Thoracic Surgery and Thoracic Oncology at the Langone NYU Medical Center, Harvey I. Pass, MD, who believes that a diagnostic tool could be a turning circuit breaker.
Scientists have found that the proteomic analysis detected 15 of 19 cases of malignant pleural mesothelioma who were in phase 1 or phase 2. Mesothelioma is a rare cancer that affects the protective lining of major organs and body cavities and is caused almost exclusively by exposure to asbestos. The pleural mesothelioma is specific to the lining of the lungs, which means that the platform specifically detects lung mesothelioma, but not necessarily the heart, chest or abdomen.
The test was considered 100% specific, meaning that there was one false positive in this study and its sensitivity was assessed at 80% to detect the presence of an early cancer. Mesothelioma is usually very difficult to detect and is usually diagnosed only when it becomes symptomatic around the scene three or four, which makes it difficult to treat and almost impossible to beat.
"Only patients who seem to benefit from treatment of mesothelioma are those who are in Stage 1 and this is only 10-15 percent of patients," said the head of the Division of Thoracic Surgery and Thoracic Oncology at the Langone NYU Medical Center, Harvey I. Pass, MD, who believes that a diagnostic tool could be a turning circuit breaker.
